Atyr PHARMA (NASDAQ:ATYR) Trading 6.1% Higher – Should You Buy?

Atyr PHARMA INC (NASDAQ:ATYR) was up 6.1% on Tuesday . The stock traded as high as $5.96 and last traded at $5.78. Approximately 663,255 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,453,813 shares. The stock had previously closed at $5.45.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ATYR. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Wednesday, June 4th. Leerink Partners started coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Price Performance

The company’s 50-day simple moving average is $3.54 and its 200-day simple moving average is $3.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market cap of $488.19 million, a price-to-earnings ratio of -5.80 and a beta of 0.88.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. On average, equities research analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ATYR. Group One Trading LLC bought a new stake in Atyr PHARMA during the fourth quarter valued at $26,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at about $37,000. Y Intercept Hong Kong Ltd acquired a new position in Atyr PHARMA in the first quarter valued at approximately $38,000. Raymond James Financial Inc. acquired a new stake in shares of Atyr PHARMA during the 4th quarter worth approximately $39,000. Finally, XTX Topco Ltd bought a new stake in Atyr PHARMA in the fourth quarter valued at $40,000. Institutional investors own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.